Peptide mixture
There is disclosed a peptide mixture suitable for eliciting an immune response. It comprises a first and a second peptide, each corresponding to a fragment of the RAS protein. Each of the first and second peptides comprises a region of at least 8 amino acids which includes position 13 of the RAS protein. Each of said regions of the first and second peptides independently has at least 6 amino acid residues, other than at said position 13, which are identical to the corresponding region of the RAS protein. Each of the first and the second peptides has a point mutation at the amino acid corresponding to said position 13. The point mutation of the first peptide is different from the point mutation of the second peptide.
1. A T-cell mixture, suitable for administration to a patient,
wherein the T-cell mixture comprises T-cells specific for:
a peptide consisting of the amino acid sequence of SEQ ID NO: 19 when presented on an MHC molecule,
a peptide consisting of the amino acid sequence of SEQ ID NO: 20 when presented on an MHC molecule,
a peptide consisting of the amino acid sequence of SEQ ID NO: 21 when presented on an MHC molecule,
a peptide consisting of the amino acid sequence of SEQ ID NO: 22 when presented on an MHC molecule,
a peptide consisting of the amino acid sequence of SEQ ID NO: 23 when presented on an MHC molecule,
a peptide consisting of the amino acid sequence of SEQ ID NO: 24 when presented on an MHC molecule,
a peptide consisting of the amino acid sequence of SEQ ID NO: 25 when presented on an MHC molecule, and
a peptide consisting of the amino acid sequence of SEQ ID NO: 26 when presented on an MHC molecule.
2. A T-cell mixture, suitable for administration to a patient,
wherein the T-cell mixture comprises T-cells specific for:
a peptide consisting of the amino acid sequence of SEQ ID NO: 27 when presented on an MHC molecule,
a peptide consisting of the amino acid sequence of SEQ ID NO: 28 when presented on an MHC molecule,
a peptide consisting of the amino acid sequence of SEQ ID NO: 29 when presented on an MHC molecule,
a peptide consisting of the amino acid sequence of SEQ ID NO: 30 when presented on an MHC molecule,
a peptide consisting of the amino acid sequence of SEQ ID NO: 31 when presented on an MHC molecule, and
a peptide consisting of the amino acid sequence of SEQ ID NO: 32 when presented on an MHC molecule.
3. A pharmaceutical composition comprising a T-cell mixture according to claim 1 , and a pharmaceutically-acceptable carrier, diluent and/or excipient.
4. A method of stimulating the immune system in a human patient with cancer, wherein the cancer is associated with RAS protein amino acid substitutions, the method comprising:
i) selecting a T-cell mixture according to claim 1 ; and
ii) administering the T-cell mixture to the patient.
5. A pharmaceutical composition comprising a T-cell mixture according to claim 2 , and a pharmaceutically-acceptable carrier, diluent and/or excipient.
6. A method of stimulating the immune system in a human patient with cancer, wherein the cancer is associated with RAS protein amino acid substitutions, the method comprising:
i) selecting a T-cell mixture according to claim 2 ; and
ii) administering the T-cell mixture to the patient.